Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
PNC-27
Preclinical
Research chemical
Summary
Chimeric peptide combining a p53 HDM-2-binding segment with a membrane-penetration motif; studied for selective cancer cell membrane disruption in preclinical oncology research.
Categories
Longevity, Immune
Mechanism
Binds membrane-associated HDM-2 on cancer cells; transmembrane domain inserts and disrupts membrane integrity leading to cell death. Distinct from classic nuclear p53 reactivation drugs.
Half-life
Research-dependent
Routes
Subcutaneous injection; Intravenous
Legal / access
Experimental anticancer research peptide. Not approved cancer therapy. Not for self-medication.
Key risks
- Unknown systemic toxicity
- Potential off-target membrane effects
Common claims
- Experimental anticancer research interest only
Select peptide B